These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

737 related items for PubMed ID: 30269322

  • 1. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
    Ji Y, Peng T, Wang G, Zhang Y, Cao M, Gao Q, Li S.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep 25; 21(9):1019-1024. PubMed ID: 30269322
    [Abstract] [Full Text] [Related]

  • 2. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y, Wang Q, Wang J, Qiao XY, Zhang J, Lin YC, Li Y, Fan LQ, Yang PG, Zhao Q.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb 25; 24(2):128-137. PubMed ID: 33508918
    [Abstract] [Full Text] [Related]

  • 3. [Effects of robotic and laparoscopic-assisted surgery on lymph node dissection and short-term outcomes in patients with Siewert II adenocarcinoma of esophagogastric junction].
    Wang D, Cao S, Tan X, Liu S, Liu X, Niu Z, Chen D, Wang D, Zhang J, Lv L, Li Y, Jiang H, Guo D, Li Y, Li Z, Zhou Y.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb 25; 22(2):156-163. PubMed ID: 30799538
    [Abstract] [Full Text] [Related]

  • 4. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN, Catalano PJ, Enzinger PC, King BL, Bueno R, Martin NE, Hong TS, Wo JY, Mamon HJ.
    Dis Esophagus; 2017 Jul 01; 30(7):1-8. PubMed ID: 28475728
    [Abstract] [Full Text] [Related]

  • 5. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
    Li J, Zhao Q, Ge X, Song Y, Tian Y, Wang S, Liu M, Qiao X.
    BMC Surg; 2021 Mar 17; 21(1):137. PubMed ID: 33731072
    [Abstract] [Full Text] [Related]

  • 6. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
    Nabavizadeh N, Shukla R, Elliott DA, Mitin T, Vaccaro GM, Dolan JP, Maggiore RJ, Schipper PH, Hunter JG, Thomas CR, Holland JM.
    Dis Esophagus; 2016 Aug 17; 29(6):614-20. PubMed ID: 26043837
    [Abstract] [Full Text] [Related]

  • 7. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
    Anderegg MCJ, van der Sluis PC, Ruurda JP, Gisbertz SS, Hulshof MCCM, van Vulpen M, Mohammed NH, van Laarhoven HWM, Wiezer MJ, Los M, van Berge Henegouwen MI, van Hillegersberg R.
    Ann Surg Oncol; 2017 Aug 17; 24(8):2282-2290. PubMed ID: 28424936
    [Abstract] [Full Text] [Related]

  • 8. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR, Hart KD, Nabavizadeh N, Bensch KG, Vaccaro GM, Thomas CR, Schipper PH, Hunter JG, Dolan JP.
    Dis Esophagus; 2017 Jul 01; 30(7):1-7. PubMed ID: 28475724
    [Abstract] [Full Text] [Related]

  • 9. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
    Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A, CROSS study group.
    Lancet Oncol; 2015 Sep 01; 16(9):1090-1098. PubMed ID: 26254683
    [Abstract] [Full Text] [Related]

  • 10. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW, Zang L, Ma JJ, Sun J, Yang X, Wang ML, Lu AG, Hu WG, Zheng MH.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb 25; 24(2):138-144. PubMed ID: 33508919
    [Abstract] [Full Text] [Related]

  • 11. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M, Hummel R, Petrova E, Knief J, Wellner UF, Keck T, Bausch D.
    World J Gastroenterol; 2018 Apr 07; 24(13):1429-1439. PubMed ID: 29632424
    [Abstract] [Full Text] [Related]

  • 12. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
    Goense L, van der Sluis PC, van Rossum PSN, van der Horst S, Meijer GJ, Haj Mohammad N, van Vulpen M, Mook S, Ruurda JP, van Hillegersberg R.
    J Surg Oncol; 2017 Jun 07; 115(7):812-820. PubMed ID: 28267212
    [Abstract] [Full Text] [Related]

  • 13. Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
    Zhao Q, Li Y, Wang J, Zhang J, Qiao X, Tan B, Tian Y, Shi G, Xu Q, Li R, Liu Y, Yang P.
    Am J Med Sci; 2015 Jun 07; 349(6):472-6. PubMed ID: 25996101
    [Abstract] [Full Text] [Related]

  • 14. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
    Zemanova M, Petruzelka L, Pazdro A, Kralova D, Smejkal M, Pazdrova G, Honova H.
    Dis Esophagus; 2010 Feb 07; 23(2):160-7. PubMed ID: 19515190
    [Abstract] [Full Text] [Related]

  • 15. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL, Meng WJ, Shu P, Deng XB, Wu B, Jiang D, Zhuang H, Shen YL, Zhou ZG, Wang ZQ, Wang X.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr 25; 22(4):349-356. PubMed ID: 31054549
    [Abstract] [Full Text] [Related]

  • 16. Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II and III adenocarcinoma of the esophagogastric junction.
    Ge X, Zhao Q, Song Y, Li J, Liu M, Bai W, Qiao X.
    Eur J Surg Oncol; 2018 Apr 25; 44(4):502-508. PubMed ID: 29395438
    [Abstract] [Full Text] [Related]

  • 17. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.
    van de Schoot L, Romme EA, van der Sangen MJ, Creemers GJ, van Lijnschoten G, van Driel OJ, Rutten HJ, Nieuwenhuijzen GA.
    Ann Surg Oncol; 2008 Jan 25; 15(1):88-95. PubMed ID: 17896144
    [Abstract] [Full Text] [Related]

  • 18. Preoperative chemoradiotherapy for esophageal or junctional cancer.
    van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, CROSS Group.
    N Engl J Med; 2012 May 31; 366(22):2074-84. PubMed ID: 22646630
    [Abstract] [Full Text] [Related]

  • 19. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S, Habermehl D, Agha A, Belka C, Combs SE, Eckel R, Friess H, Gerbes A, Nüssler NC, Schepp W, Schmid RM, Schmitt W, Schubert-Fritschle G, Weber B, Werner J, Engel J.
    Strahlenther Onkol; 2018 Feb 31; 194(2):125-135. PubMed ID: 29071366
    [Abstract] [Full Text] [Related]

  • 20. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY, Zhang P, Zhang BL, Wang X, Xu XZ, Zheng S, Wang JY, Cai RG, Yuan P, Ma F, Fan Y, Xu BH.
    Zhonghua Zhong Liu Za Zhi; 2012 Oct 31; 34(10):770-4. PubMed ID: 23291072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.